Answers are grounded in this paper and cite their sources.
The FDA removes the suicidal warning from GLP-1 agonists, suggesting safer usage for weight management.
The FDA has requested the removal of the suicidal behavior and ideation warning from the labels of the three glucagon-like peptide-1 (GLP-1) receptor agonists approved for chronic weight management: liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Zepbound). The warning was initially included in the labels of these drugs based on an increased risk of suicidal behavior and ideation observed with older drugs for weight management.
No takes yet. Share an insight, caveat, or question.
A 2026 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: